WHICH OF YOUR NVAF PATIENTS ARE RIGHT FOR WATCHMAN?

01 Increased Risk for Stroke & Recommended for Anticoagulation (CHA$_2$DS$_2$-VASc $\geq$ 2)

Yes $\Rightarrow$ No

02 Suitable for warfarin

Yes $\Rightarrow$ No

03 Patient Has Appropriate Rationale To Seek a Non-Pharmacologic Alternative to warfarin

Yes $\Rightarrow$ No

Patient May Be a Candidate for the WATCHMAN™ LAAC Device*

*Payer coverage policies may not be consistent with BSC device labeling. In some cases, payer policies may include procedures, indications or criteria (such as a specific definition of CHADS$_2$ or CHA$_2$DS$_2$-VASc scores or contraindication to warfarin) which may differ from the FDA label.
 Specific factors may include one or more of the following:

- History of major bleeding while taking anticoagulation therapy
- Patient’s prior experience with OAC (if applicable):
  - Inability to maintain stable INR
  - Inability to comply with regular INR monitoring and unavailability of an approved alternative OAC
- Medical condition, occupation, or lifestyle placing patient at high risk of major bleeding secondary to trauma
- Presence of indication(s) for long-term warfarin use, other than non-valvular atrial fibrillation (e.g. mechanical heart valve, hypercoagulable states, recurrent deep venous thrombosis)
Specific factors that need to be considered for the WATCHMAN Device and implantations procedure include:

- Overall medical status, including conditions which might preclude the safety of a percutaneous procedure
- Suitability for percutaneous, trans-septal procedures, including considerations of:
  - Cardiac anatomy relating to the LAA size and shape
  - Vascular access anatomy
  - Ability to tolerate general or local anesthesia
  - Ability to undergo required imaging
- Ability to comply with recommended post-WATCHMAN Device implant pharmacologic regimen

**WATCHMAN™ LAAC Device**

**Patient Selection for Treatment**

**POST-PROCEDURE THERAPY**
- Warfarin + ASA (81 mg) daily
- Clopidogrel (75 mg) + ASA (325 mg) daily

**IMPLANT**

**45 DAYS**

**DESTINATION THERAPY**
- ASA (325 mg) daily

**6 MONTHS**

*If leak >5 mm, patients remained on warfarin + ASA until seal documented, skipping the clopidogrel + ASA pharmacotherapy.
**Indications for use**

The WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who:

- Are at increased risk for stroke and systemic embolism based on CHADS₂ or CHA₂DS₂-VASc scores and are recommended for anticoagulation therapy;
- Are deemed by their physicians to be suitable for warfarin; and
- Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin.

The WATCHMAN Access System is intended to provide vascular and transseptal access for all WATCHMAN Left Atrial Appendage Closure Devices with Delivery Systems.

**Contraindications**

Do not use the WATCHMAN Device if:

- Intracardiac thrombus is visualized by echocardiographic imaging.
- An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.
- The LAA anatomy will not accommodate a device. See Table 46 in the DFU.
- Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.
- There are contraindications to the use of warfarin, aspirin, or clopidogrel.
- The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section) such that the use of the WATCHMAN Device is contraindicated.

**Warnings**

- Device selection should be based on accurate LAA measurements obtained using fluoro and ultrasound guidance (TEE recommended) in multiple angles (e.g., 0°, 45°, 90°, 135°).
- Do not release the WATCHMAN Device from the core wire if the device does not meet all release criteria.
- If thrombus is observed on the device, warfarin therapy is recommended until resolution of thrombus is demonstrated by TEE.
- The potential for device embolization exists with cardioversion <30 days following device implantation. Verify device position post-cardioversion during this period.
- Administer appropriate endocarditis prophylaxis for 6 months following device implantation. The decision to continue endocarditis prophylaxis beyond 6 months is at physician discretion.
- For single use only. Do not reuse, reprocess, or resterilize.

**Precautions**

- The safety and effectiveness (and benefit-risk profile) of the WATCHMAN Device has not been established in patients for whom long-term anticoagulation is determined to be contraindicated.
- The LAA is a thin-walled structure. Use caution when accessing the LAA and deploying the device.
- Use caution when introducing the WATCHMAN Access System to prevent damage to cardiac structures.
- Use caution when introducing the Delivery System to prevent damage to cardiac structures.
- To prevent damage to the Delivery Catheter or device, do not allow the WATCHMAN Device to protrude beyond the distal tip of the Delivery Catheter when inserting the Delivery System into the Access Sheath.
- If using a power injector, the maximum pressure should not exceed 100 psi.
- In view of the concerns that were raised by the RE-ALIGN1 study of dabigatran in the presence of prosthetic mechanical heart valves, caution should be used when prescribing oral anticoagulants other than warfarin in patients treated with the WATCHMAN Device. The WATCHMAN Device has only been evaluated with the use of warfarin post-device implantation.
ADVERSE EVENTS
Potential adverse events (in alphabetical order) which may be associated with the use of a left atrial appendage closure device or implantation procedure include but are not limited to:
Air embolism, Airway trauma, Allergic reaction to contrast media/medications or device materials, Altered mental status, Anemia requiring transfusion, Anesthesia risks, Angina, Anoxic encephalopathy, Arrhythmias, Atrial septal defect, AV fistula, Bruising, hematoma or seroma, Cardiac perforation, Chest pain/discomfort, Confusion post procedure, Congestive heart failure, Contrast related nephropathy, Cranial bleed, Decreased hemoglobin, Deep vein thrombosis, Death, Device embolism, Device fracture, Device thrombosis, Edema, Excessive bleeding, Fever, Groin pain, Groin puncture bleed, Hematuria, Hemoptysis, Hypotension, Hypoxia, Improper wound healing, Inability to reposition, recapture, or retrieve the device, Infection/pneumonia, Interaltrial septum thrombus, Intratracheal bleeding, Major bleeding requiring transfusion, Misplacement of the device/improper seal of the appendage / movement of device from appendage wall, Myocardia erosion, Nausea, Oral bleeding, Pericardial effusion / tamponade, Pleural effusion, Prolonged bleeding from a laceration, Pseudoaneurysm, Pulmonary edema, Renal failure, Respiratory insufficiency/failure, Surgical removal of the device, Stroke – Ischemic, Stroke – Hemorrhagic, Systemic embolism, TEE complications (throat pain, bleeding, esophageal trauma), Thrombocytopenia, Thrombosis, Transient ischemic attack (TIA), Valvular damage, Vasovagal reactions.
There may be other potential adverse events that are unforeseen at this time.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Directions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.


For more information, please visit: WATCHMAN.com/HCP